TAILOR MADE BIORESORBABLE URETERAL STENTS HydrUStent
Caixa Empreender Award | HydrUStent (BGI)
Jul 15, 2015
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
TAILOR MADE BIORESORBABLE URETERAL STENTS
HydrUStent
2
An Aqua Urological product
2
DO YOU WANT TO HAVE THIS IN YOUR BODY?
“Currently nearly 100% of the people
who have an urological stent are likely
to develop a bacterial infection within
30 days, which increases morbidity
threefold”
*www.dolcera.com (2007))
3
An Aqua Urological product
3
HydrUStent
FOR patients who need temporary stents,
WHO need to have a second surgery for stent removal,
OUR PRODUCT is a degradable stent,
THAT PROVIDES lower treatment cost
UNLIKE our competitors
OUR PRODUCT avoids a second surgery.
Benefits
Reduced costs
Reduced risk of
infection
Increased patient
comfort
4
An Aqua Urological product
ValidationQUESTIONS YES COMMENTS
Do you have experience of complains of
Low Urinary Track Symptoms (LUTS)
in your patients with double J ureteral
stents?
100% --------
Do you think your patients would be
happy if it would be possible to avoid a
second term intervention for stent
removal?
92%
“I think the stents are quite disabling. A more flexible stent would help”
Dr.Deepak Batura
Consultant Urological Surgeon at Ealing Hospital NHS Trust
Do you think it would be beneficial the
existence of biodegradable double J
ureteral stents?
100%
“This would solve the problem of the cystoscopy for removal as well as
that of the "forgotten stent"”
Dr. Günter Janetschek,
Dept. of Urology, Salzburg Medical School
Would you be willing to use
biodegradable stents as long as their
safety and ease of placement would be
demonstrated?
100% -------
Do you consider that the introduction in
the market of a biodegradable stent
would definitely change the current
clinical practice in urology?
80%
“Another great advantage is that it does not need a second surgery, to
remove the stent, and so the patient has no job loss or admission to
hospital, facilitates recovery and professional and social integration.
There is a reduction in costs for the health system.”
Dr. La Fuente
Santo António Hospital, Porto, Portugal
Survey conducted to a
group of medical doctors
from the board
European Association
of Urology
section Uro-technology.
5
An Aqua Urological product
Competitive Landscape
HydrUstentBoston
ScientificC.R. Bard Coloplast Cook Medical
Products and services Ureteral stents Medical devices Medical devices Medical devices Medical devices
Net Sales - € 5,791 M1 € 2,436 M1 € 4,200 k € 1,590 M
Net Income - € 475 M € 551 M € 1,100 k
Target market
(urological sales)- €386 M €588 M €151,000 k
Annual growth (%) - 5% 3% 6% 7%
R&D investment 12% 9.7% 11%
Competitive advantage Degradable stentHydrogel stent with
reduced risk of infection--- ---
Hydrogel stent with
reduced risk of infection
State of development In vivo validation Market Market Market Market
.
[1] US Dollars to Euros the exchange rate used was 0.7882 USD/EUR
6
An Aqua Urological product
6
Competitive analysis
137.5 K surgical procedures
avoided/per year
=
€ 0.15 B
7
An Aqua Urological product
7
98 K /year
stents placed in EUROPE
39.5 K /year
stents placed in U.S.
A Global Market –Urological Stents
Market segments for urological stents %Indwelling time
(days)
Ureteroscopic lithotripsy 74% 7-14
Percutaneous nephrolithotomy 12% 7-14
Uncomplicated Kidney Stones management 8% 2-3
Benign ureteral stenosis 2% --
Others 4% --
0
20
40
60
80
100
120
Eu
rop
e
EU
A
Oth
er
reg
ion
s
Eu
rop
e
EU
A
Oth
er
reg
ion
s
Eu
rop
e
EU
A
Oth
er
reg
ion
s
Eu
rop
e
EU
A
Oth
er
reg
ion
s
2019 2020 2021 2022
Milh
are
s S
tents Serviceable Market
Ureteroscopic lithotripsy Uncomplicated Kidney Stones management
8
An Aqua Urological product
Business Model
USERS:
Patients
HydrUStent
Key activities:
Marketing
R&D
Production
Key resources:
Know-how
IP
Suppliers
Manufacturing
R&D
Marketing
Distribution
€ €
DOCTORS
PROVIDERS:
Hospitals
PAYERS:
Insurance Companies
National Health systems
€
€
€
€€
9
An Aqua Urological product
-2
-1
0
1
2
3
4
5
6
7
8
2015 2016 2017 2018 2019 2020 2021 2022
Revenues 4 years sales projections
Break Even = 6 Years | NPV@ 20% = € 2, 000 k
Start
selling
2019
Million (€)
Sales Forecast
Accumulated cash flow
10
An Aqua Urological product
Milestones and Funding Needs
Funding Needs FIRST ROUND OF INVESTIMENT 275 k€ SECOND ROUND OF INVESTIMENT 1,331 k€
11
An Aqua Urological product
ALEXANDRE BARROS
PhD Student
3Bs Research Group
RITA DUARTE
Assistant researcher
3Bs Research Group
ESTEVÃO LIMA
Director
Department of
Urology,
Hospital of Braga
Director
3Bs Research Group
CEng, MSc, PhD,
DSc, MD (Doctor h.c)
Team in Place Ready to Go
RUI L. REIS
12
An Aqua Urological product
3B´s Research Group
AvePark, Zona Industrial da Gandra, S. Cláudio do Barco
4806-909 Caldas das Taipas, Guimarães, Portugal
Tel: +351 253 510915 (Direct) or +351 253 510900
Fax: +351 253 510909
Reach Us@ AquaUrological Company
Related Documents
